Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Shows 19% of Breast Cancer Patients Don’t Receive Recommended Radiation After Mastectomy

February 19, 2009
Publication
Article
OncologyONCOLOGY Vol 23 No 2
Volume 23
Issue 2

One-fifth of women who should receive radiation after a mastectomy are not getting this potentially lifesaving treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

One-fifth of women who should receive radiation after a mastectomy are not getting this potentially lifesaving treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

The study looked at 396 women who were treated with a mastectomy for breast cancer. The researchers found that 19% of women who fell clearly within guidelines recommending radiation after the mastectomy did not receive that treatment. Results of the study appear online in the journal Cancer and will be published in the March 15 issue.

Postmastectomy radiation is known to decrease the risk of cancer returning in the chest wall and has been shown to reduce mortality in high-risk patients, but there has been some debate within the cancer community about who is likely to benefit most. Current guidelines recommend radiation after mastectomy for women who had particularly large tumors or cancer in four or more of their nearby lymph nodes. Even women with fewer positive lymph nodes should strongly consider radiation treatment.

Potentially Lifesaving Treatment
“There’s an identifiable high-risk group for whom there’s absolutely no debate-they need radiation after their mastectomy. Even in this group for whom it’s crystal clear, we found that only four-fifths were treated. That’s not good enough. This is a potentially lifesaving treatment,” says lead study author Reshma Jagsi, MD, DPhil, assistant professor of radiation oncology at the U-M Medical School.

The most common reason women cited for not considering radiation therapy was that their doctors did not recommend it. “Much attention has been focused on educating people that they need radiation after lumpectomy. But many women assume having a mastectomy means radiation won’t be needed. That’s not always the case, and patients choosing one surgery over another hoping to avoid radiation need to be aware of this,” Jagsi says.

Articles in this issue

Adjuvant Therapy for Colorectal Cancer: Increasingly Complex as Patients Age
A Man With Changes in the Urinary Bladder: Benign Metaplasia or Adenocarcinoma?
A Man With Changes in the Urinary Bladder: Benign Metaplasia or Adenocarcinoma?
First-Line Maintenance With Erlotinib/Bevacizumab Improves Progression-Free Survival in Advanced Lung Cancer
Study Shows 19% of Breast Cancer Patients Don’t Receive Recommended Radiation After Mastectomy
Toward Evidence-Based Management of the Dermatologic Effects of EGFR Inhibitors
Toward Evidence-Based Management of the Dermatologic Effects of EGFR Inhibitors
The Growing Importance of Skin Toxicity in EGFR Inhibitor Therapy
In Search of Rigorous Data on How to Palliate the EGFR Inhibitor–Induced Rash
Endocrine Therapy in 2009: Consideration of the Tumor and the Host
Predicting Endocrine Responsiveness: Novel Biomarkers on the Horizon
Adjuvant Chemotherapy for Colon Cancer in the Elderly: Moving From Evidence to Practice
How Should We Care for Elderly Cancer Patients?
Acai Berry
Acai Berry
Predicting Endocrine Therapy Responsiveness in Breast Cancer
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Advertisement

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.

FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer

Russ Conroy
September 25th 2025
Article

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Though overall survival (OS) was at approximately 16% maturity at data cutoff, a favorable trend for the T-DXd regimen has been observed.

The FDA Grants Priority Review to T-DXd/Pertuzumab in 1L Metastatic Breast Cancer

Tim Cortese
September 24th 2025
Article

Results from the phase 3 DESTINY-Breast09 trial will support the FDA’s decision on whether to approve T-DXd plus pertuzumab in frontline metastatic breast cancer.


Employing Comprehensive Genomic Testing in the NSCLC Paradigm

Employing Comprehensive Genomic Testing in the NSCLC Paradigm

ONCOLOGY Staff
September 24th 2025
Article

An expert discusses the vital role of comprehensive genomic profiling in personalizing treatment for non-small cell lung cancer, enhancing patient outcomes.

Related Content
Advertisement

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.

FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer

Russ Conroy
September 25th 2025
Article

Data from the phase 3 EMBER-3 trial support the approval of imlunestrant in this breast cancer population.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Though overall survival (OS) was at approximately 16% maturity at data cutoff, a favorable trend for the T-DXd regimen has been observed.

The FDA Grants Priority Review to T-DXd/Pertuzumab in 1L Metastatic Breast Cancer

Tim Cortese
September 24th 2025
Article

Results from the phase 3 DESTINY-Breast09 trial will support the FDA’s decision on whether to approve T-DXd plus pertuzumab in frontline metastatic breast cancer.


Employing Comprehensive Genomic Testing in the NSCLC Paradigm

Employing Comprehensive Genomic Testing in the NSCLC Paradigm

ONCOLOGY Staff
September 24th 2025
Article

An expert discusses the vital role of comprehensive genomic profiling in personalizing treatment for non-small cell lung cancer, enhancing patient outcomes.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.